DUBLIN--(BUSINESS WIRE)--
Research and Markets (http://www.researchandmarkets.com/research/vlhmzc/randd_trends_auti) has announced the addition of the "R&D Trends: Autism Spectrum Disorders - Pipeline Growth Reflects Increasing Interest in Autism" report to their offering.
This report reviews the key trends in the autism spectrum disorders pipeline. The analysis is intended to support R&D decision-making by evaluating the dynamics of the pipeline and hypothesizing future treatments of autism spectrum disorders.
The autism spectrum disorders (ASDs) market is a challenging one to penetrate; since 2006 only two products have been successful in entering this marketplace: Risperdal (risperidone; Johnson & amp; Johnson) and Abilify (aripiprazole; Bristol-Myers Squibb). However, as additional agents near the market, increasing interest in ASDs has led to a sizable growth in the clinical pipeline.
Scope
- Overview of drugs in late- and early-stage clinical development for autism spectrum disorders.
- Identification of the target product profile for future autism spectrum disorders treatments.
- Summary of clinical trial design in autism spectrum disorders including exploration of key endpoints and assessment methodology.
- Identification of key challenges associated with the conduct of clinical trials in autism spectrum disorders.
- Exploration of future treatment in autism spectrum disorders including the development of personalized treatments and the use of biomarkers.